InnoCare Pharma (HKSE:09969) Pre-Tax Income : HK$-232.9 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. InnoCare Pharma's pretax income for the three months ended in Dec. 2023 was HK$-114.8 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-232.9 Mil. InnoCare Pharma's pretax margin was -52.15%.

During the past 7 years, InnoCare Pharma's highest Pretax Margin was -1.93%. The lowest was -334666.94%. And the median was -28727.89%.

InnoCare Pharma Pre-Tax Income Historical Data

The historical data trend for InnoCare Pharma's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Pre-Tax Income Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-2,392.81

-464.53

-24.64

-998.04

-704.62

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial											-443.76	-57.04	-	-118.11	-114.76

Competitive Comparison of InnoCare Pharma's Pre-Tax Income

For the Biotechnology subindustry, InnoCare Pharma's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCare Pharma's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's Pre-Tax Income falls into.

InnoCare Pharma Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

InnoCare Pharma's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-710.642	+	0	+	-38.316	+	210.37	+	-166.031
	=	-704.6

InnoCare Pharma's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-147.138	+	0	+	0.952	+	0	+	31.428
	=	-114.8

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-232.9 Mil.

InnoCare Pharma (HKSE:09969) Pre-Tax Income Explanation

InnoCare Pharma's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-114.758	/	220.041
	=	-52.15%

During the past 7 years, InnoCare Pharma's highest Pretax Margin was -1.93%. The lowest was -334666.94%. And the median was -28727.89%.

InnoCare Pharma Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (HKSE:09969) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (HKSE:09969) Headlines

No Headlines